A New Era of Medicine

Gene therapy represents a new paradigm in human health, with the potential to resolve unmet medical needs by addressing the underlying causes of disease.

Our Company

AVROBIO, Inc., a leader in lentiviral-based gene therapies, is a clinical stage company developing disruptive therapies that have the potential to transform patients’ lives in a single dose. The Company is focused on the development of its clinical stage programs in Fabry disease and acute myeloid leukemia (AML), while actively building a pipeline of gene therapies to treat Gaucher disease and other rare diseases.

Rare Disease Technology Overview

The Great Potential of Gene Therapy

Gene therapies have been shown to deliver dramatic disease-modifying effects and potentially life-long cures from a single infusion of genetically-modified cells. Underpinning these advances are a deep understanding of cell biology, immunology and advanced vector designs enabling safe and effective delivery of therapeutic genes targeted to specific cells.